Lexicon Pharmaceuticals (LXRX) Financials: Revenue & Earnings
LXRX$1.48-0.01 -0.34%
$656.31M
Market Cap
—
P/E
—
Forward P/E
—
Score
Lexicon Pharmaceuticals (LXRX) Financials: Revenue & Earnings
LXRX price $1.48 -0.01 -0.34%
- Ticker
- LXRX
- Price
- $1.48
- Change
- -0.01 -0.34%
- Market cap ?
- $656.31M
- Beta ?
- 1.08
- Sector
- Healthcare
- Industry
- Biotechnology
Fair value
LXRX fair value $0.52. Price $1.48. Price is 186% above fair value.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Starting free cash flow 11.48M. Growth 0.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 10.23% (beta 1.1). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 444.96M. Net debt 27.91M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Model uncertainty high for this stock
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-05 | — | -0.06 | — | 4.14M |
| 2026-08-06 | -0.06 | -0.05 | 692.00K | 3.99M |
| 2026-05-07 | -0.00 | -0.04 | 21.10M | 9.79M |
| 2026-03-05 | -0.04 | -0.07 | 5.49M | 3.14M |
| 2025-11-06 | -0.04 | -0.07 | 14.18M | 3.14M |
| 2025-08-06 | 0.01 | -0.08 | 28.87M | 5.81M |
| 2025-05-13 | -0.07 | -0.10 | 1.26M | 1.31M |
| 2025-03-06 | -0.09 | -0.11 | 26.55M | 2.82M |
| 2024-11-12 | -0.18 | -0.17 | 1.75M | 6.48M |
| 2024-08-01 | -0.17 | -0.18 | 1.65M | 8.16M |
| 2024-05-02 | -0.20 | -0.18 | 1.13M | 1.40M |
| 2024-03-11 | -0.20 | -0.23 | 702.00K | 1.24M |
| 2023-11-08 | -0.21 | -0.22 | 162.00K | 4.79M |
| 2023-08-03 | -0.22 | -0.17 | 317.00K | 4.06M |
| 2023-05-02 | -0.17 | -0.17 | 24.00K | 30.00K |
| 2023-03-02 | -0.16 | -0.14 | 28.00K | 50.00K |
| 2022-11-09 | -0.13 | -0.15 | 39.00K | 50.00K |
| 2022-08-02 | -0.16 | -0.15 | 35.00K | 100.00K |
| 2022-05-05 | -0.16 | -0.16 | 37.00K | 50.00K |
| 2022-02-28 | -0.17 | -0.17 | 14.00K | 14.78K |
| 2021-11-03 | -0.16 | -0.18 | 23.00K | 120.00K |
| 2021-07-30 | -0.13 | -0.16 | 234.00K | 10.00K |
| 2021-05-06 | -0.15 | -0.17 | 27.00K | 110.00K |
| 2021-03-10 | -0.05 | -0.28 | 199.00K | — |
| 2020-10-29 | 0.70 | 0.26 | 6.63M | 8.71M |
| 2020-07-30 | -0.64 | -0.57 | 9.16M | 8.60M |
| 2020-04-27 | -0.63 | -0.66 | 8.00M | 8.76M |
| 2020-03-12 | -0.48 | -0.76 | 8.73M | 12.83M |
| 2019-11-07 | 2.11 | 0.73 | 294.45M | 110.23M |
| 2019-07-31 | -0.22 | -0.09 | 9.68M | 3.52M |
| 2019-05-01 | -0.21 | -0.21 | 9.22M | 9.65M |
| 2019-03-13 | -0.16 | -0.28 | 17.07M | 31.52M |
| 2018-11-01 | -0.26 | -0.32 | 6.86M | 8.84M |
| 2018-07-30 | -0.33 | -0.35 | 13.75M | 14.22M |
| 2018-05-03 | -0.40 | -0.42 | 25.21M | 28.57M |
| 2018-02-22 | -0.31 | -0.43 | 33.05M | 52.24M |
| 2017-11-08 | -0.29 | -0.36 | 26.94M | 33.39M |
| 2017-08-01 | -0.33 | -0.45 | 12.05M | 16.13M |
| 2017-05-02 | -0.31 | -0.44 | 18.29M | 23.29M |
| 2017-03-03 | -0.31 | -0.51 | 23.04M | 31.87M |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-03 | Swain Judith L | Buy | 89.31K | — | — |
| 2026-06-03 | Swain Judith L | Sell | 89.31K | — | — |
| 2026-06-03 | Sullivan Diane E. | Buy | 89.31K | — | — |
| 2026-06-03 | Sullivan Diane E. | Sell | 89.31K | — | — |
| 2026-06-03 | SOBECKI CHRISTOPHER J | Buy | 89.31K | — | — |
| 2026-06-03 | SOBECKI CHRISTOPHER J | Sell | 89.31K | — | — |
| 2026-06-03 | Cheung Ivan | Buy | 89.31K | — | — |
| 2026-06-03 | Cheung Ivan | Sell | 89.31K | — | — |
| 2026-06-03 | BARKER SAM L | Buy | 89.31K | — | — |
| 2026-06-03 | BARKER SAM L | Sell | 89.31K | — | — |
| 2026-06-03 | Amouyal Philippe | Buy | 89.31K | — | — |
| 2026-06-03 | Amouyal Philippe | Sell | 89.31K | — | — |
| 2026-06-03 | DEBBANE RAYMOND | Buy | 89.31K | — | — |
| 2026-06-03 | DEBBANE RAYMOND | Sell | 89.31K | — | — |
| 2026-05-01 | Amouyal Philippe | Buy | 43.48K | $1.61 | 70.00K |
| 2026-05-01 | Amouyal Philippe | Buy | 35.71K | — | — |
| 2026-05-01 | SOBECKI CHRISTOPHER J | Buy | 43.48K | $1.61 | 70.00K |
| 2026-05-01 | SOBECKI CHRISTOPHER J | Buy | 35.71K | — | — |
| 2026-05-01 | BARKER SAM L | Buy | 43.48K | $1.61 | 70.00K |
| 2026-05-01 | BARKER SAM L | Buy | 35.71K | — | — |
| 2026-05-01 | Cheung Ivan | Buy | 43.48K | $1.61 | 70.00K |
| 2026-05-01 | Cheung Ivan | Buy | 35.71K | — | — |
| 2026-05-01 | Swain Judith L | Buy | 43.48K | $1.61 | 70.00K |
| 2026-05-01 | Swain Judith L | Buy | 35.71K | — | — |
| 2026-05-01 | Sullivan Diane E. | Buy | 43.48K | $1.61 | 70.00K |
| 2026-05-01 | Sullivan Diane E. | Buy | 35.71K | — | — |
| 2026-05-01 | DEBBANE RAYMOND | Buy | 43.48K | $1.61 | 70.00K |
| 2026-05-01 | DEBBANE RAYMOND | Buy | 35.71K | — | — |
| 2026-04-30 | Artal Participations S.a r.l. | Buy | 20.42M | — | — |
| 2026-04-30 | Artal Participations S.a r.l. | Buy | 408.43K | — | — |
| 2026-04-30 | Artal Participations S.a r.l. | Sell | 408.43K | — | — |
| 2026-02-28 | McDermott Wendy | Buy | 144.39K | — | — |
| 2026-02-28 | McDermott Wendy | Sell | 144.39K | — | — |
| 2026-02-28 | McDermott Wendy | Sell | 68.11K | $1.47 | 100.12K |
| 2026-02-28 | McDermott Wendy | Buy | 52.32K | — | — |
| 2026-02-28 | McDermott Wendy | Buy | 27.70K | — | — |
| 2026-02-28 | McDermott Wendy | Sell | 52.32K | — | — |
| 2026-02-28 | McDermott Wendy | Sell | 27.70K | — | — |
| 2026-02-28 | Martens Rachel Yap | Sell | 67.09K | — | — |
| 2026-02-28 | Martens Rachel Yap | Buy | 67.09K | — | — |
| 2026-02-28 | Martens Rachel Yap | Sell | 35.83K | $1.47 | 52.66K |
| 2026-02-28 | Granowitz Craig B | Buy | 202.26K | — | — |
| 2026-02-28 | Granowitz Craig B | Sell | 202.26K | — | — |
| 2026-02-28 | Granowitz Craig B | Sell | 109.10K | $1.47 | 160.37K |
| 2026-02-28 | Granowitz Craig B | Buy | 74.23K | — | — |
| 2026-02-28 | Granowitz Craig B | Buy | 35.79K | — | — |
| 2026-02-28 | Granowitz Craig B | Sell | 74.23K | — | — |
| 2026-02-28 | Granowitz Craig B | Sell | 35.79K | — | — |
| 2026-02-28 | Gopinathan Suma | Buy | 65.64K | — | — |
| 2026-02-28 | Gopinathan Suma | Sell | 24.34K | $1.47 | 35.78K |
| 2026-02-28 | Gopinathan Suma | Sell | 65.64K | — | — |
| 2026-02-28 | Gopinathan Suma | Buy | 20.31K | — | — |
| 2026-02-28 | Gopinathan Suma | Buy | 14.00K | — | — |
| 2026-02-28 | Gopinathan Suma | Sell | 20.31K | — | — |
| 2026-02-28 | Gopinathan Suma | Sell | 14.00K | — | — |
| 2026-02-28 | DeFrancesco Lisa | Sell | 128.19K | — | — |
| 2026-02-28 | DeFrancesco Lisa | Buy | 128.19K | — | — |
| 2026-02-28 | DeFrancesco Lisa | Sell | 74.57K | $1.47 | 109.62K |
| 2026-02-28 | DeFrancesco Lisa | Buy | 24.67K | — | — |
| 2026-02-28 | DeFrancesco Lisa | Sell | 24.67K | — | — |
| 2026-02-28 | Crum Brian T | Buy | 170.16K | — | — |
| 2026-02-28 | Crum Brian T | Sell | 105.02K | $1.47 | 154.38K |
| 2026-02-28 | Crum Brian T | Buy | 33.46K | — | — |
| 2026-02-28 | Crum Brian T | Sell | 170.16K | — | — |
| 2026-02-28 | Crum Brian T | Buy | 69.39K | — | — |
| 2026-02-28 | Crum Brian T | Sell | 69.39K | — | — |
| 2026-02-28 | Crum Brian T | Sell | 33.46K | — | — |
| 2026-02-28 | Coiante Scott M | Sell | 160.24K | — | — |
| 2026-02-28 | Coiante Scott M | Buy | 160.24K | — | — |
| 2026-02-28 | Coiante Scott M | Sell | 54.88K | $1.47 | 80.68K |
| 2026-02-28 | Exton Michael | Sell | 503.26K | — | — |
| 2026-02-28 | Exton Michael | Buy | 503.26K | — | — |
| 2026-02-28 | Exton Michael | Sell | 204.83K | $1.47 | 301.10K |
| 2026-02-25 | DEBBANE RAYMOND | Buy | 2.00K | $1.49 | 2.98K |
| 2026-02-23 | DEBBANE RAYMOND | Buy | 100.00K | $1.47 | 147.00K |
| 2026-02-20 | DEBBANE RAYMOND | Buy | 100.00K | $1.48 | 147.79K |
| 2026-02-19 | DEBBANE RAYMOND | Buy | 50.00K | $1.44 | 71.97K |
| 2026-02-18 | DEBBANE RAYMOND | Buy | 133.69K | $1.32 | 176.47K |
| 2026-02-17 | Artal Participations S.a r.l. | Buy | 41.29K | $65.00 | 2.68M |
| 2026-02-17 | DEBBANE RAYMOND | Buy | 76.86K | $1.31 | 100.54K |
| 2026-02-13 | DEBBANE RAYMOND | Buy | 57.95K | $1.31 | 75.88K |
| 2026-02-12 | McDermott Wendy | Buy | 375.30K | $1.37 | 514.16K |
| 2026-02-12 | McDermott Wendy | Buy | 250.20K | — | — |
| 2026-02-12 | Martens Rachel Yap | Buy | 290.62K | $1.37 | 398.15K |
| 2026-02-12 | Martens Rachel Yap | Buy | 193.74K | — | — |
| 2026-02-12 | Granowitz Craig B | Buy | 519.92K | $1.37 | 712.29K |
| 2026-02-12 | Granowitz Craig B | Buy | 346.61K | — | — |
| 2026-02-12 | Gopinathan Suma | Buy | 357.68K | $1.37 | 490.02K |
| 2026-02-12 | Gopinathan Suma | Buy | 238.45K | — | — |
| 2026-02-12 | DeFrancesco Lisa | Buy | 386.30K | $1.37 | 529.23K |
| 2026-02-12 | DeFrancesco Lisa | Buy | 257.53K | — | — |
| 2026-02-12 | Crum Brian T | Buy | 449.56K | $1.37 | 615.90K |
| 2026-02-12 | Crum Brian T | Buy | 299.71K | — | — |
| 2026-02-12 | Coiante Scott M | Buy | 409.02K | $1.37 | 560.36K |
| 2026-02-12 | Coiante Scott M | Buy | 272.68K | — | — |
| 2026-02-12 | Exton Michael | Buy | 1.29M | $1.37 | 1.77M |
| 2026-02-12 | Exton Michael | Buy | 862.44K | — | — |
| 2026-02-02 | Avicenna Life Sci Master Fund LP | Other | 0 | — | — |
| 2026-02-02 | Invus Global Management, LLC | Buy | 18.55M | $1.30 | 24.12M |
| 2026-02-02 | Invus Global Management, LLC | Buy | 3.85M | $1.30 | 5.00M |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 156, holders +15 vs prior quarter. Ownership 91.59%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| ARTAL GROUP S.A. | 175.16M | 20.42M | +13.20% | 420.37M |
| FMR LLC | 51.78M | 6.73M | +14.93% | 124.28M |
| SIREN, L.L.C. | 44.30M | 0 | 0.00% | 106.33M |
| SESSA CAPITAL IM, L.P. | 18.96M | 1.05M | +5.85% | 45.51M |
| BLACKROCK, INC. | 17.35M | 14.03M | +422.20% | 41.64M |
| VANGUARD CAPITAL MANAGEMENT LLC | 9.90M | 382.04K | +4.01% | 23.76M |
| POINT72 ASSET MANAGEMENT, L.P. | 8.25M | 436.72K | +5.59% | 19.80M |
| GEODE CAPITAL MANAGEMENT, LLC | 6.24M | 3.08M | +97.04% | 14.99M |
| STATE STREET CORP | 4.92M | 3.95M | +410.12% | 11.80M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.36M | 1.81M | +331.35% | 5.66M |
| NORTHERN TRUST CORP | 1.97M | 1.47M | +297.97% | 4.72M |
| SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. | 1.96M | 1.96M | New | 4.70M |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.96M | 645.48K | +49.22% | 4.70M |
| VANGUARD FIDUCIARY TRUST CO | 1.63M | 302.29K | +22.69% | 3.92M |
| CITADEL ADVISORS LLC | 1.60M | 1.56M | +3933.20% | 3.84M |
| ISHARA INVESTMENTS LP | 1.27M | 369.00K | +40.91% | 3.05M |
| MILLENNIUM MANAGEMENT LLC | 1.13M | -3.81M | -77.06% | 2.72M |
| RENAISSANCE TECHNOLOGIES LLC | 1.13M | -473.50K | -29.58% | 2.70M |
| MACKENZIE FINANCIAL CORP | 963.35K | 190.68K | +24.68% | 2.31M |
| ADAR1 CAPITAL MANAGEMENT, LLC | 750.00K | 0 | 0.00% | 1.80M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 696.78K | 612.38K | +725.56% | 1.67M |
| ACADIAN ASSET MANAGEMENT LLC | 696.62K | 251.33K | +56.44% | 1.67M |
| UBS GROUP AG | 684.71K | -1.80M | -72.43% | 1.64M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 668.50K | 584.10K | +692.06% | 1.60M |
| TWO SIGMA INVESTMENTS, LP | 643.44K | -556.19K | -46.36% | 1.54M |
Earnings and financials
Lexicon Pharmaceuticals, Inc. (LXRX) trades at $1.48, with a market cap of $656.31M and a trailing P/E of n/a. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Insights · Dividends · Forecast · Financials · Learn